Neidio i'r cynnwys
VuFind
    • English
    • Deutsch
    • Español
    • Français
    • Italiano
    • 日本語
    • Nederlands
    • Português
    • Português (Brasil)
    • 中文(简体)
    • 中文(繁體)
    • Türkçe
    • עברית
    • Gaeilge
    • Cymraeg
    • Ελληνικά
    • Català
    • Euskara
    • Русский
    • Čeština
    • Suomi
    • Svenska
    • polski
    • Dansk
    • slovenščina
    • اللغة العربية
    • বাংলা
    • Galego
    • Tiếng Việt
    • Hrvatski
    • हिंदी
    • Հայերէն
    • Українська
    • Sámegiella
    • Монгол
Uwch
  • Response to the letter by Prof...
  • Dyfynnu hwn
  • Anfonwch hwn fel neges destun
  • E-bostio hwn
  • Argraffu
  • Allforio Cofnod
    • Allforio i RefWorks
    • Allforio i EndNoteWeb
    • Allforio i EndNote
  • Permanent link
Response to the letter by Prof Jonathan Deeks to the Lancet EClinicalMedicine editor

Response to the letter by Prof Jonathan Deeks to the Lancet EClinicalMedicine editor

Manylion Llyfryddiaeth
Prif Awduron: Leber, W, Lammel, O, Panovska-Griffiths, J, Czypionka, T
Fformat: Journal article
Iaith:English
Cyhoeddwyd: Elsevier 2021
  • Daliadau
  • Disgrifiad
  • Eitemau Tebyg
  • Dangos Staff

Eitemau Tebyg

  • Response to the letter by Prof Jonathan Deeks to the Lancet EClinicalMedicine editor
    gan: Werner Leber, et al.
    Cyhoeddwyd: (2021-10-01)
  • Corrigendum to ‘Oral Azvudine for hospitalised patients with COVID-19 and pre-existing conditions: a retrospective cohort study.’ [EClinicalMedicine 59 (2023) 101981]
    gan: Yuming Sun, et al.
    Cyhoeddwyd: (2023-08-01)
  • Corrigendum to “Real-world long-term outcomes in individuals at clinical risk for psychosis: The case for extending duration of care” [EClinicalMedicine 28 (2020) 100,578]
    gan: Paolo Fusar-Poli, et al.
    Cyhoeddwyd: (2021-02-01)
  • Corrigendum to Antiviral effect of high-dose ivermectin in adults with COVID-19: A proof-of-concept randomized trial [EClinicalMedicine 37 (2021) 100,959]”
    gan: Alejandro Krolewiecki, et al.
    Cyhoeddwyd: (2021-09-01)
  • Corrigendum to “Nitazoxanide superiority to placebo to treat moderate COVID-19 – A Pilot prove of concept randomized double-blind clinical trial.” [EClinicalMedicine 37 (2021) 100981]
    gan: Vinicius Fontanesi Blum, MD, MSc, et al.
    Cyhoeddwyd: (2021-11-01)

Opsiynau Chwilio

  • Hanes Chwilio
  • Chwiliad Uwch

Canfod Mwy

  • Pori'r Catalog
  • Pori yn ôl y Wyddor
  • Archwiliwch Sianeli
  • Cronfeydd y Cwrs
  • Eitemau Newydd

Angen Help?

  • Awgrymiadau Chwilio
  • Gofynnwch i Lyfrgellydd
  • Cwestiynau Cyffredin